S
Susanne Saußele
Researcher at Heidelberg University
Publications - 38
Citations - 4457
Susanne Saußele is an academic researcher from Heidelberg University. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 18, co-authored 37 publications receiving 3659 citations.
Papers
More filters
Journal ArticleDOI
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Rüdiger Hehlmann,Astghik Voskanyan,Michael Lauseker,Markus Pfirrmann,Lida Kalmanti,Sebastien Rinaldetti,Katharina Kohlbrenner,Claudia Haferlach,Brigitte Schlegelberger,Alice Fabarius,Wolfgang Seifarth,Birgit Spieß,Patrick Wuchter,Stefan W. Krause,Hans-Jochem Kolb,Andreas Neubauer,Dieter K. Hossfeld,Christoph Nerl,Alois Gratwohl,Gabriela M. Baerlocher,Andreas Burchert,Tim H. Brümmendorf,Jörg Hasford,Andreas Hochhaus,Susanne Saußele,Michele Baccarani,Sakk +26 more
TL;DR: High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems and mortality was lower with earlier treatment.
Book ChapterDOI
Molecular Monitoring of Residual Disease in Chronic Myelogenous Leukemia Patients After Therapy
TL;DR: A stepwise strategy for diagnosis and follow-up of CML patients employing molecular methods is suggested and RT-PCR is suggested as the method of choice for monitoring patients after bone marrow transplantation (BMT).
Journal ArticleDOI
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
Michael Lauseker,Benjamin Hanfstein,Claudia Haferlach,Susanne Schnittger,Markus Pfirrmann,Alice Fabarius,Brigitte Schlegelberger,Susanne Saußele,Christian Dietz,Philipp Erben,Rüdiger Hehlmann,Joerg Hasford,Andreas Hochhaus,Martin C. Müller +13 more
TL;DR: The results suggest that there is no one-to-one cutoff for BCR-ABLIS representing CCyR, but patients are advised to use the 1 % CML-Study IV level according to the international scale in order to avoid misclassification ofCCyR patients.
Journal ArticleDOI
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Ulrike Proetel,Nadine Pletsch,Michael Lauseker,Martin C. Müller,Benjamin Hanfstein,Stefan W. Krause,Lida Kalmanti,Annette Schreiber,Dominik Heim,Gabriela M. Baerlocher,Wolf-Karsten Hofmann,Elisabeth Lange,Hermann Einsele,Martin Wernli,Stephan Kremers,Rudolf Schlag,Lothar Müller,Mathias Hänel,Hartmut Link,Bernd Hertenstein,Markus Pfirrmann,Andreas Hochhaus,Joerg Hasford,Rüdiger Hehlmann,Susanne Saußele +24 more
TL;DR: It is suggested that the optimal dose for older patients with chronic myeloid leukemia in chronic phase is higher than 400 mg/day, compared to standard dose imatinib with which older patients achieved remissions much later than younger patients.
Journal ArticleDOI
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia
Anne-Sophie Bouillon,Mónica S. Ventura Ferreira,Shady Adnan Awad,Johan Richter,Andreas Hochhaus,Volker Kunzmann,Jolanta Dengler,Jeroen Janssen,Gert J. Ossenkoppele,Peter E. Westerweel,Peter A. W. te Boekhorst,Francois-Xavier Mahon,Henrik Hjorth-Hansen,Susanne Isfort,Thoas Fioretos,Sebastian Hummel,Mirle Schemionek,Stefan Wilop,Steffen Koschmieder,Susanne Saußele,Satu Mustjoki,Fabian Beier,Tim H. Brümmendorf +22 more
TL;DR: Proof of principle for accelerated telomere shortening in LSC as opposed to HSC in CML patients at diagnosis is provided and the use of TL in leukemic cells as a prognostic parameter pending prospective validation is supported.